- Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
- Berger BT, Labriola MK, Antonarakis ES, Armstrong AJ.
- BMJ Case Rep. 2023 Jan 18;16(1):e251320. doi: 10.1136/bcr-2022-251320.
- PMID: 36653039
- PubMed abstract
- Source abstract
- Case report